An open-label, randomized, single-dose, three-way crossover bioavailability study comparing DFN-02 with subcutaneous sumatriptan in healthy volunteers.

Trial Profile

An open-label, randomized, single-dose, three-way crossover bioavailability study comparing DFN-02 with subcutaneous sumatriptan in healthy volunteers.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs DFN 02 (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Sep 2016 New trial record
    • 10 Sep 2016 Results of pooled analysis of effect of permeation enhancer on pharmacokinetics of sumatriptan from this and another trial (CTP 700276590) published in the Headache.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top